AI Article Synopsis
- VEGF is a crucial target in cancer treatment, but the cardiovascular safety of anti-VEGF/VEGFR therapies poses significant challenges due to limited definitions and understanding of toxicity.
- The text reviews the cardiovascular toxicity associated with these therapies, discussing clinical diagnoses, management practices, and ongoing research into possible toxicological mechanisms.
- The author emphasizes the need for guidelines to effectively prevent and manage cardiovascular risks, underscoring the importance of this knowledge for patient safety and future drug development.
Article Abstract
Introduction: Vascular endothelial growth factor (VEGF) is a key target in cancer therapy. However, cardiovascular safety has been one of the most challenging aspects of anti-VEGF/VEGF receptor (VEGFR) agent development and therapy. While accurate diagnostic modalities for assessment of cardiac function have been developed over the past few decades, a lack of an optimal definition and precise mechanism still places a significant limit on the effective management of cardiovascular toxicity.
Areas Covered: Here, we report the cardiovascular toxicity profile associated with anti-VEGF/VEGFR agents and summarize the clinical diagnoses as well as management that are already performed in clinical practice or are currently being investigated. Furthermore, the review discusses the potential molecular toxicological mechanisms, which may provide strategies to prevent toxicity and drive drug discovery.
Expert Opinion: Cardiovascular toxicity associated with anti-VEGF/VEGFR agents has been a substantial risk for cancer treatment. To improve its management, the development of guidelines for prevention, monitoring and treatment of cardiovascular toxicity has become a hot topic. The summary of cardiovascular toxicity profile, mechanisms and management given in this review is not only significant for the optimal use of existing anti-VEGF/VEGFR agents to protect patients predisposed to cardiovascular toxicity but is also beneficial for drug development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17425255.2020.1787986 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrating melt electrospinning writing and microfluidics to engineer a human cardiac microenvironment for high-fidelity drug screening.
Bioact Mater
March 2025
Academy of Medical Engineering and Translational Medicine, Tianjin University, 300072, China.
The preclinical evaluation of drug-induced cardiotoxicity is critical for developing novel drug, helping to avoid drug wastage and post-marketing withdrawal. Although human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and the engineered heart organoid have been used for drug screening and mimicking disease models, they are always limited by the immaturity and lack of functionality of the cardiomyocytes. In this study, we constructed a Cardiomyocytes-on-a-Chip (CoC) that combines micro-grooves (MGs) and circulating mechanical stimulation to recapitulate the well-organized structure and stable beating of myocardial tissue.
View Article and Find Full Text PDFAlterations in the inflammatory homeostasis of aging-related cardiac dysfunction and Alzheimer's diseases.
FASEB J
January 2025
Department of Physiology and Biophysics, Mississippi Center for Heart Research, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Alzheimer's disease (AD) is well known among the elderly and has a profound impact on both patients and their families. Increasing research indicates that AD is a systemic disease, with a strong connection to cardiovascular disease. They share common genetic factors, such as mutations in the presenilin (PS1 and PS2) and the apolipoprotein E (APOE) genes.
View Article and Find Full Text PDFSystematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer.
Cell Mol Biol Lett
January 2025
School of Pharmacy, Southwest Medical University, Luzhou, 646000, China.
Hypoxia-inducible factors (HIFs) are essential transcription factors that orchestrate cellular responses to oxygen deprivation. HIF-1α, as an unstable subunit of HIF-1, is usually hydroxylated by prolyl hydroxylase domain enzymes under normoxic conditions, leading to ubiquitination and proteasomal degradation, thereby keeping low levels. Instead of hypoxia, sometimes even in normoxia, HIF-1α translocates into the nucleus, dimerizes with HIF-1β to generate HIF-1, and then activates genes involved in adaptive responses such as angiogenesis, metabolic reprogramming, and cellular survival, which presents new challenges and insights into its role in cellular processes.
View Article and Find Full Text PDFThe Traditional Applications, Phytochemistry, Pharmacology, Pharmacokinetics, Quality Control and Safety of Paeoniae Radix Alba: A Review.
Am J Chin Med
December 2024
College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250355, P. R. China.
Paeoniae Radix Alba (PRA, called Baishao in China) is the dried root of Pall. In clinical practice, PRA has been used to treat cardiovascular disease, menstrual disorders, abdominal pain, diarrhea, and liver disease, among other conditions. This review provides a systematic summary of its traditional uses, geographical distribution and current cultivation situation, phytochemistry, pharmacokinetics, pharmacology, quality control, and toxicology.
View Article and Find Full Text PDFPBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study.
Leuk Lymphoma
January 2025
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
This retrospective study aimed to evaluate the efficacy and safety of PBVD (pegylated liposomal doxorubicin [PLD], bleomycin, vinblastine, and dacarbazine) in the first-line treatment of classical Hodgkin lymphoma (cHL) patients with cardiovascular risk factors. Overall, 84 patients (53 had stage I-II and 31 had stage III-IV disease) received PBVD. The median PLD treatment duration was 16 weeks (interquartile range [IQR]: 8-24) for stage I-II and 24 weeks (IQR: 12-24) for stage III-IV.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!